KdT Ventures — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Faeth Therapeutics is a clinical-stage oncology company developing therapies that inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway.
BiotechHealthtechAustin, US
Anand Parikh(Executive Officer, Director, Promoter)Oliver Maddocks(Executive Officer, Director)
BoardAlex Morgan(Director)inJayson Dallas(Director)Robert Gould(Director)Stephen Hahn(Director)
Co-investorsAble PartnersAtacama VenturesCota CapitalFuture VenturesiSelect FundS2G Investments+4 more
Syenex provides cell delivery technologies and contract development services for therapeutic cell engineering, serving biopharmaceutical companies developing cell-based therapies.
BiotechDeep TechMedical DevicesEvanston, US
John D. Rosanelli(Executive Officer, Director)
Co-investorsAlleyCorpAlley Robotics Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.